Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE 76 versus HYPAQUE CYSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE 76 versus HYPAQUE CYSTO.
HYPAQUE-76 vs HYPAQUE-CYSTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-76 (diatrizoate meglumine and diatrizoate sodium) is an ionic iodinated contrast agent that attenuates X-rays, providing radiographic contrast. Its mechanism involves high iodine content (76%) that absorbs X-rays, distinguishing anatomical structures in imaging procedures.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Intravenous: 50-100 mL (as a 76% solution, 370 mg iodine/mL) for contrast imaging, administered as a bolus or infusion; maximum 300 mL per procedure.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
None Documented
None Documented
Terminal elimination half-life of 1.5-2 hours in normal renal function. Prolonged to >10 hours in moderate renal impairment (CrCl 30-50 mL/min). Closely correlates with creatinine clearance.
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Primarily renal; >95% excreted unchanged in urine within 24 hours via glomerular filtration. Fecal excretion minimal (<5%). Biliary excretion negligible.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent